Umbilical cord blood is emerging as a valuable source of stem cells, offering potential cures for life-threatening diseases. Stem cells possess remarkable plasticity, capable of transforming into various cell types and even organs within the body. This adaptability makes them promising candidates for treating a wide range of illnesses.
While stem cells are abundant in embryos, adult stem cells also exist, primarily in the brain. However, extracting these adult stem cells is challenging due to their dispersed nature.
Cord blood stem cells offer a more accessible alternative. The extraction process is safe and straightforward, performed after the baby’s birth and umbilical cord is cut, posing no risk to the mother or child.
T cells, crucial for fighting infections, develop when stem cells pass through the thymus gland. Patients lacking sufficient T cells are vulnerable to severe infections. Cord blood stem cells can regenerate T cells and other vital cells, bolstering the body’s defense mechanisms. Matching the stem cells to the patient’s blood type is crucial for successful transfusion, and using the patient’s own cord blood guarantees compatibility.
The umbilical cord’s stem cell matrix, known as Wharton’s jelly, is rich in primitive stem cells. These undifferentiated cells are highly effective for transfusion. Animal studies, particularly on pigs, have demonstrated the viability of using cord blood stem cells. The journal “Stem Cells” provides extensive data on stem cell research and related topics.
Currently, leukemia and anemia are the most common conditions treated with stem cell transfusions. Ongoing research suggests potential applications for Parkinson’s disease, multiple sclerosis, and various cancers.